Epoch Investment Partners Inc. Has $664,000 Position in Boston Scientific Co. (NYSE:BSX)

Epoch Investment Partners Inc. raised its holdings in Boston Scientific Co. (NYSE:BSX) by 10.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 8,616 shares of the medical equipment provider’s stock after acquiring an additional 840 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Boston Scientific were worth $664,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Putnam Investments LLC boosted its position in shares of Boston Scientific by 110.5% in the 4th quarter. Putnam Investments LLC now owns 13,067,570 shares of the medical equipment provider’s stock worth $755,436,000 after purchasing an additional 6,859,280 shares during the last quarter. Capital World Investors boosted its holdings in Boston Scientific by 236.1% during the fourth quarter. Capital World Investors now owns 9,419,829 shares of the medical equipment provider’s stock worth $544,560,000 after buying an additional 6,617,360 shares during the last quarter. Capital Research Global Investors acquired a new position in shares of Boston Scientific during the 1st quarter worth about $182,897,000. Vanguard Group Inc. increased its stake in shares of Boston Scientific by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 127,437,884 shares of the medical equipment provider’s stock valued at $8,728,221,000 after acquiring an additional 1,988,082 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado raised its position in shares of Boston Scientific by 11,484.5% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 1,705,468 shares of the medical equipment provider’s stock valued at $98,593,000 after acquiring an additional 1,690,746 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, July 25th. Raymond James lifted their target price on Boston Scientific from $91.00 to $94.00 and gave the stock a “strong-buy” rating in a report on Wednesday, September 4th. Royal Bank of Canada restated an “outperform” rating and issued a $85.00 price target on shares of Boston Scientific in a report on Thursday, July 25th. Evercore ISI lifted their price objective on Boston Scientific from $78.00 to $81.00 and gave the company an “outperform” rating in a report on Tuesday, July 2nd. Finally, The Goldman Sachs Group initiated coverage on Boston Scientific in a research note on Thursday, May 30th. They set a “buy” rating and a $90.00 target price for the company. Three investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $86.65.

Boston Scientific Price Performance

NYSE:BSX opened at $84.00 on Tuesday. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $84.89. The stock’s 50 day moving average price is $78.84 and its two-hundred day moving average price is $74.84. The firm has a market capitalization of $123.24 billion, a price-to-earnings ratio of 70.59, a P/E/G ratio of 2.75 and a beta of 0.79.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.04. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The business had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. During the same quarter last year, the firm posted $0.53 EPS. The company’s quarterly revenue was up 14.5% on a year-over-year basis. On average, analysts anticipate that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Insider Buying and Selling

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $77.30, for a total transaction of $539,785.90. Following the completion of the sale, the executive vice president now directly owns 42,908 shares in the company, valued at $3,316,788.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders sold 20,949 shares of company stock valued at $1,627,877. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.